CrossrefInfokarte
Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma
Journal of Clinical and Experimental Hematopathology · 2026 · 66 (1) · 63-68
DOI: 10.3960/jslrt.25065 ↗Abstract
Kein Abstract verfügbar.
EUVIMED